Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series

Luigi Di Lauro, Patrizia Vici, Maddalena Barba, Laura Pizzuti, Domenico Sergi, Daniele Sergi, Massimo Rinaldi, Anna Di Benedetto, Isabella Sperduti, Abeer M. Shaaban, Valerie Speirs, Marcella Mottolese, Ruggero De Maria Marchiano, Marcello Maugeri-Saccà

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

20 Citazioni (Scopus)


Male breast cancer is a rare disease treated as hormone receptor-positive female breast cancer. The characterization of breast cancer at the molecular level has lately revealed gender-related differences. As the androgen receptor is emerging as a potential oncogenic driver in male breast cancer, we analyzed efficacy data from metastatic patients treated with antiandrogens. We evaluated the activity of cyproterone acetate, either as a monotherapy or combined with a GnRH analog, in 36 metastatic male breast cancer patients. Fourteen patients were treated with cyproterone acetate as monotherapy and 22 patients with complete androgen blockade. We recorded 4 complete responses and 15 partial responses, for an overall response rate of 52.8 % (95 % CI, 36.5-69.4). Stable disease was reported in 11 patients. Median PFS was 8.9 months (95 % CI, 6.1-11.7), and median OS was 24.3 months (95 % CI, 22.5-26.1). Data on androgen receptor expression were available for 7 patients. All the 4 patients with androgen receptor-expressing tumors had a clinical benefit, including a patient with an estrogen receptor-negative disease. Conversely, none of the 3 patients with androgen receptor-negative tumors had a tumor response. Antiandrogen-based therapy showed efficacy in metastatic male breast cancer patients. Our results encourage considering antiandrogens in the therapeutic continuum, especially if supported by androgen receptor expression.
Lingua originaleEnglish
pagine (da-a)73-80
Numero di pagine8
RivistaBreast Cancer Research and Treatment
Stato di pubblicazionePubblicato - 2014


  • Metastatic male breast cancer Antiandrogens Cyproterone acetate GnRH analogs Androgen receptor


Entra nei temi di ricerca di 'Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series'. Insieme formano una fingerprint unica.

Cita questo